In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiObex Inc.

www.diobex.com

Latest From DiObex Inc.

2010 Scrip 100 - Survivors of the shakeout

Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.

Metabolic Disorders Cancer

Enject's GlucaPen: Mightier than the Hypo-kit?

Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.

Enject's GlucaPen: Mightier than the Hypo-kit?

Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.
BioPharmaceutical

DiObex Inc.

DiObex Inc. is named for the diseases its founders hope to treat-diabetes, obesity, and syndrome X, a poorly understood precursor to Type II diabetes. The company has in-licensed and is developing two products: DIO-901, a long-acting glucagon to prevent insulin-induced hypoglycemia in Type I diabetics, and DIO-902, a cortisol synthesis inhibitor to treat metabolic disorders such as Type II diabetes and syndrome X.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • DiObex Inc.
  • Senior Management
  • David Cory, CEO
    Daniel T Green, Pres.
    Bruce W Carlson, VP, Fin.
    Bernice R Welles, MD, VP, Dev.
    Timothy A Stewart, PhD, VP, Res.
  • Contact Info
  • DiObex Inc.
    Phone: (415) 551-0400
    600 Townsend St.
    Ste. 271
    San Francisco, CA 94103
    USA
UsernamePublicRestriction

Register